EXHIBIT 99.1

PRESS RELEASE

CONTACTS:                  Timothy Dahltorp
                           Chief Executive Officer
                           Xtrana, Inc.
                           (303) 466-4424

FOR IMMEDIATE RELEASE

                XTRANA ANNOUNCES THE SALE OF ITS PATENT PORTFOLIO

Broomfield,  CO - January 29, 2004 -- XTRANA, Inc. (OTCBB: XTRN) announced today
that it has entered into a definitive  agreement to sell all of its intellectual
property  for  $4,000,000.  These  assets  include all of Xtrana's  intellectual
property assets, excluding Xtrana's trademarks and trade names.

         Completion  of the sale is subject  to a number of closing  conditions,
including the approval of a majority of Xtrana's stockholders to be solicited at
a Special Meeting of Stockholders scheduled for March this year.

         Tim Dahltorp,  Xtrana's CEO  commented,  "After an extensive  review of
alternatives  available to the Company,  including raising  additional  capital,
licensing,  co-development  partnerships,  and  the  sale  of part or all of the
Company's  assets,  the Board of Directors  concluded  the sale of the Company's
Intellectual  Property provided the best economic benefit to the Company and its
shareholders." Mr. Dahltorp continued,  "The proceeds from the transaction could
attract interest from other operating  businesses that might benefit from access
to those funds, as well as our tax loss carry forward and our status as a public
company with a clean reporting history. Such interest could result in us merging
or  otherwise  joining  together  with an existing  business  that could  create
long-term stockholder value. After closing the transaction,  it is the intention
of the  Board  of  Directors  to spend a  reasonable  period  of time  exploring
opportunities  to find other  transactions  that it believes  would provide long
term stockholder  value, and if no such transactions are identified,  to propose
that the stockholders  approve a liquidation with the proceeds being distributed
to  shareholders.  In either event,  the Board of Directors  does not anticipate
taking any action without further stockholder  approval."

Xtrana,  Inc.  develops,  manufactures and markets novel nucleic acid extraction
kits and detection  systems for use in molecular  diagnostics,  drug  discovery,
forensics,  research,  clinical and life sciences  markets.  To learn more about
Xtrana, visit the Company's web site at www.xtrana.com.

This Press Release contains forward-looking  statements (identified by the words
"estimate,"  "anticipate," "expect," "believe," and similar expressions),  which
are based upon management's  current  expectations and speak only as of the date
made. These forward-looking  statements are subject to risks,  uncertainties and
factors that could cause actual  results to differ  materially  from the results
anticipated in the forward-looking  statements and include,  but are not limited
to, competitors'  pricing strategies and technological  innovations,  changes in
health care and government  regulations,  litigation  claims,  foreign  currency
fluctuation,  product  acceptance,  as well as other  factors  discussed  in the
Company's last Report on Form 10-KSB.